Biomarker Discovery

Overview

TrilliumBiO translates biomarker discoveries into clinical and commercial success through tailored solutions for healthcare innovators. We design and validate biomarkers, standalone or aligned with drug pipelines, to accelerate time-to-market, bridging the gap between discovery and commercialization. Our biomarker solutions include rare diseases, a widely underdiagnosed area of healthcare that TrilliumBiO is committed to supporting through discovery and validation. Work with cutting-edge platforms to validate biomarkers with real-world clinical applications.

Over 50% of FDA drug approvals include biomarker-driven indications.

Drug candidates with biomarker-based patient selection are 3x more likely to succeed in Phase III trials, reducing late-stage failures.

Biomarkers are critical for early detection where time-sensitive intervention improves patient outcomes

Our Biomarker Discovery Approach

A common challenge brought to TrilliumBiO:

Organizations often face hurdles when bringing specialized diagnostic tests to market. Barriers typically include cost constraints, long development timelines, limited global accessibility, and rigid sample or system requirements.

TrilliumBiO’s solutions:

Our approach balances scientific rigor with practical considerations, delivering results fast—often in under six months.

Our approach includes:

Designing flexible assays that support multiple sample types for broader patient access
Ensuring global compatibility through thoughtful logistics and international readiness
Providing robust support through education, documentation, and ongoing collaboration

DRUG DEVELOPMENT ACCELERATION & CLINICAL TRIALS BENEFIT Reduce costs and time in clinical trials with predictive and pharmacodynamic biomarkers.	REAL-TIME DISEASE MONITORING Track disease progression and treatment response with greater accuracy.
ADVANCING SCIENTIFIC UNDERSTANDING Unlock novel insights into disease mechanisms, paving the way for breakthrough discoveries.	FASTER MARKET ADOPTION Simplify regulatory approval leveraging TrilliumBiO's expertise and platforms.

DRUG DEVELOPMENT ACCELERATION & CLINICAL TRIALS BENEFIT
Reduce costs and time in clinical trials with predictive and pharmacodynamic biomarkers.

REAL-TIME DISEASE MONITORING
Track disease progression and treatment response with greater accuracy.

ADVANCING SCIENTIFIC UNDERSTANDING
Unlock novel insights into disease mechanisms, paving the way for breakthrough discoveries.

FASTER MARKET ADOPTION
Simplify regulatory approval leveraging TrilliumBiO's expertise and platforms.

Rare Disease Biomarker Discovery

Rare diseases impact over 300 million people worldwide, yet they remain significantly underdiagnosed and undertreated.

TrilliumBiO has a proven track record of addressing solving complex diagnostic challenges, including those associated with rare diseases. We help address the rare disease community’s unique set of challenges through tailored, customizable biomarker solutions. TrilliumBiO develops niche diagnostics, by prioritizing and understanding the needs of the patient and provider. We partner to increase awareness and access in the rare disease community.

10,000+ distinct types of Rare and Genetic Diseases with 1 in 10 People are Affected by Rare Disease

95% of Rare Diseases Lack an FDA Approved Treatment

The economic impact of a delayed diagnosis can be over $500,000 in avoidable costs per patient

Faster & More Accurate Diagnosis – Over 50% of rare disease patients face diagnostic delays of 5-7 years. Improved testing reduces the diagnostic odyssey.